How to Audit Your Import Export Controls for Restricted Products Process Before Inspectors Do

Context

The import and export of restricted products, particularly controlled substances, is tightly regulated across global markets. Regulatory authorities such as the FDA in the United States, EMA in the European Union, and MHRA in the United Kingdom maintain stringent guidelines to ensure that substances that may pose public health risks are managed effectively. This article serves as a comprehensive guide for Regulatory Affairs professionals, CMC, and Labelling teams to navigate the complexities involved in maintaining compliance with import export controls for restricted products.

Legal/Regulatory Basis

The legal framework governing the import and export of controlled substances is primarily defined by national laws and international treaties, complemented by detailed regulatory guidelines.

• United States (FDA): Under the Controlled Substances Act (CSA), the FDA regulates the import and export of controlled substances. Key provisions can be found in Title 21 of the Code of Federal Regulations (CFR), particularly 21 CFR Part 1301, which governs registration for manufacturers and distributors, and 21 CFR Part 1312 on import and export controls.
• European Union (EMA): The EU operates under the EU Directive 2001/83/EC and Regulation (EC) No 726/2004. These regulations detail the licensing requirements and permit obligations for substances categorized as controlled under the EU drug framework.
• United Kingdom (MHRA): The UK’s regulations on controlled substances are similarly structured to the EU legislations. The Misuse of Drugs Act (1971) and the accompanying regulations outline procedures governing import and export activities.
• International Treaties: Compliance with the United Nations Single Convention on Narcotic Drugs (1961) and the Convention on Psychotropic Substances (1971) is also essential, as these treaties require participating nations to control the international trade of narcotic and psychotropic substances.

Documentation

Thorough documentation is a cornerstone of compliance with import and export controls. Regulatory Affairs professionals must ensure that all necessary documents are accurately prepared, submitted, and maintained. The following are critical documentation components:

• Licenses and Registrations: Maintain all relevant licenses, including those issued for import/export activities. For the US, ensure compliance with the registration processes laid out in 21 CFR Part 1301.
• Shipping Documentation: All shipments should be accompanied by appropriate shipping documents, including import/export declarations, packing lists, and commercial invoices that detail the nature of the products and their compliance status.
• Chain of Custody Records: Accurate records demonstrating the chain of custody for all controlled substances must be maintained. This typically involves tracking the product from the production facility, through transportation, to the end-user or storage facility.
• Import/Export Permits: Depending on the nature of the substance, specific permits may be required. Uphold compliance with all necessary permitting to mitigate any risk of delay in the approvals process.
• Tracking and Auditing Records: Ensure systematic tracking and storage of documentation to facilitate audits and inspections. Implement electronic recordkeeping systems for better compliance tracking.

Review/Approval Flow

The regulatory process for importing and exporting controlled substances typically involves several stages, each requiring meticulous review and adherence to legal requirements. The flow outlined below highlights key decision points for Regulatory Affairs teams:

Step 1: Preliminary Assessment

Before initiating imports or exports, conduct a preliminary assessment to determine:

• The legal classification of the substance involved.
• If the product is subject to any existing trade restrictions.
• Whether the import or export aligns with good practice guidelines.

Step 2: Prepare Documentation

As detailed in the documentation section, gather necessary documents in accordance with local and international laws. Pay particular attention to:

• Completeness and accuracy of licenses.
• Verification of shipping documents and permits.
• Chain of custody tracking.

Step 3: Submit Applications

Upon ensuring documentation completeness, submit all applications to the relevant regulatory authorities. Anticipate processing delays, particularly when applications require intergovernmental coordination, such as those necessitating DEA approval in the U.S. This adds a layer of complexity that should be factored into submission timelines.

Step 4: Compliance Monitoring

Throughout the import/export phase, actively monitor for compliance. Adherence to outlined protocols is vital, and documentation should be readily accessible for review.

Step 5: Inspection and Auditing Readiness

Prepare for potential audits by regulatory agencies. Regular internal audits will identify gaps in documentation and compliance, ensuring that corrective measures can be taken before external inspections.

Common Deficiencies

Despite the rigorous adherence required for compliance, oversight can occur. The following are common deficiencies identified during inspections:

• Incomplete or Erroneous Documentation: Failing to have the necessary import/export permits or licenses can lead to significant consequences, including shipment holds or seizure.
• Poor Recordkeeping: Inadequate chain of custody records, missing documentation, or a failure to track inventory can raise red flags during inspections.
• Lack of Staff Training: Employees must be trained on the specific compliance requirements pertaining to controlled substances to prevent errors. A lack of proper training often leads to operational gaps in compliance.
• Insufficient Handling of Regulatory Changes: Changes in legislation or regulatory guidance can impact compliance requirements. Regularly update processes to align with evolving regulations.

RA-Specific Decision Points

In the regulatory landscape, several key decision points necessitate careful consideration to assure compliance and avoid delays:

When to File as Variation vs. New Application

Regulatory Affairs professionals must discern whether a change to an existing product or substance requires a variation application or constitutes a new application. Key considerations include:

• If the alteration impacts the product’s classification or its active ingredient, a new application may be warranted.
• Routine amendments that do not alter product safety or efficacy can often be submitted as variations.
• Reference the specific agency guidelines for a concrete understanding of thresholds between variations and new applications.

Justifying Bridging Data

In some cases, sufficient data from another jurisdiction can be utilized, reducing the need for duplicate studies. To justify this bridging of data:

• Ensure that the foreign study adheres to local regulatory standards and scientific validity.
• Provide robust documentation demonstrating the relevance of the foreign data to the local context.
• Anticipate agency inquiries regarding data applicability and ensure comprehensive justifications are available.

Practical Tips for Documentation, Justifications, and Responses to Agency Queries

To ensure inspection readiness and compliance regarding import/export controls for restricted products, consider the following practical tips:

• Regularly Review Regulatory Guidelines: Consistently stay updated on guidelines from relevant authorities such as the FDA, EMA, and MHRA.
• Implement Compliance Training: Promote a culture of compliance by conducting regular training sessions that focus on import/export regulations, documentation best practices, and specific agency expectations.
• Conduct Mock Audits: Run internal audits simulating regulatory inspections to identify vulnerabilities in documentation and processes.
• Use Compliance Software: Employ compliance and document management systems to streamline recordkeeping and ensure real-time access to critical documents.
• Establish Communication Protocols: Create streamlined lines of communication between Regulatory Affairs and other functions including CMC, Clinical, PV, QA, and Commercial teams to facilitate thorough and timely compliance actions.

Conclusion

Conducting regular audits of your import export controls for restricted products process is essential to ensure compliance with stringent regulations governing controlled substances. By understanding the legal framework, maintaining thorough documentation, and being prepared for inspections, Regulatory Affairs professionals can mitigate risks associated with non-compliance.

With precise decision-making at critical junctures, justified justifications, and careful preparation of responses to agency queries, compliance can be effectively managed. As regulatory landscapes continue to evolve, constant vigilance will remain a hallmark of successful regulatory affairs practices in the pharmaceutical and biotech industries.